Olson Jeffrey L, Velez-Montoya Raul, Bhandari Ramanath
Ophthalmology Department, University of Colorado School of Medicine, Rocky Mountain Lions Eye Institute, Aurora, CO, USA.
Department of Ophthalmology, Springfield Clinic, Springfield, IL, USA.
Transl Vis Sci Technol. 2014 Nov 3;3(6):3. doi: 10.1167/tvst.3.6.3. eCollection 2014 Oct.
To assess the capabilities of a new glaucoma drainage device regulator in controlling fluid flow as well as to demonstrate that this effect may be titratable by noninvasive means.
A rigid eye model with two main ports was used. On the first port, we placed a saline solution column. On the second, we placed a glaucoma shunt. We then measured the flow and flow rate through the system. After placing the regulator device on the tip of the tube, we measured again with the intact membrane and with the membrane open 50% and 100%. For the ex vivo testing we used a similar setting, using a cadaveric porcine eye, we measured again the flow and flow rate. However, this time we opened the membrane gradually using laser shots. A one-way analysis of variance and a Fisher's Least Significant Difference test were used for statistical significance. We also calculated the correlation between the numbers of laser shots applied and the main outcomes.
The flow through the system with the glaucoma drainage device regulator (membrane intact and 50% open) was statistically lower than with the membrane open 100% and without device ( < 0.05). The flow was successfully controlled by the number of laser shots applied, and showed a positive correlation (+ 0.9). The flow rate was almost doubled every 10 shots and statistically lower than without device at all time ( < 0.05).
The glaucoma drainage device regulator can be controlled noninvasively with laser, and allows titratable control of aqueous flow.
Initial results and evidence from this experiment will justify the initiation of in vivo animal trials with the glaucoma drainage device regulator; which brings us closer to possible human trials and the chance to significantly improve the existing technology to treat glaucoma surgically.
评估一种新型青光眼引流装置调节器控制液体流动的能力,并证明这种效果可以通过非侵入性手段进行调节。
使用具有两个主要端口的刚性眼模型。在第一个端口上,我们放置了一个盐溶液柱。在第二个端口上,我们放置了一个青光眼分流器。然后我们测量了通过该系统的流量和流速。在将调节器装置放置在管尖后,我们再次测量了完整膜以及膜打开50%和100%时的情况。对于离体测试,我们使用了类似的设置,使用猪尸体眼,我们再次测量了流量和流速。然而,这次我们使用激光射击逐渐打开膜。使用单因素方差分析和Fisher最小显著差异检验来确定统计学意义。我们还计算了应用的激光射击次数与主要结果之间的相关性。
使用青光眼引流装置调节器(膜完整且打开50%)时通过系统的流量在统计学上低于膜打开100%且无装置时(<0.05)。流量通过应用的激光射击次数成功控制,并显示出正相关(+0.9)。流速每10次射击几乎翻倍,并且在所有时间点在统计学上均低于无装置时(<0.05)。
青光眼引流装置调节器可以通过激光进行非侵入性控制,并允许对房水流动进行可调节控制。
该实验的初步结果和证据将为使用青光眼引流装置调节器启动体内动物试验提供依据;这使我们更接近可能的人体试验,并有可能显著改进现有技术以进行青光眼手术治疗。